[11th Retrovirus Conference in San Francisco, 8-11 February 2004. II. Therapeutic strategies, therapeutic side effects, development and transmission of viral resistance, HCV-coinfection].
Marcus
U
U
Robert Koch-Institut, Berlin. marcusu@rki.de
D044966:Anti-Retroviral Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D018562:Disease Transmission, Infectious / Q000517:prevention & control*; D024882:Drug Resistance, Viral; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy / Q000821:virology; D006801:Humans; D012190:Retroviridae / Q000235:genetics*; D012192:Retroviridae Infections / Q000150:complications / Q000188:drug therapy* / Q000635:transmission* / Q000821:virology; D012495:San Francisco
D044966:Anti-Retroviral Agents
11. Retroviruskonferenz in San Francisco, 8.-11. Februar 2004. Teil II: Therapiestrategien, Therapienebenwirkungen, virale Resistenzentwicklung und Resistenzübertragung, HCV-Koinfektion.